On 17 November 2026 the European Medicines Agency updated its EU recommendations for the 2026/2027 seasonal influenza vaccine composition to cover mRNA (nucleic acid-based) influenza vaccines, and refreshed Annex I, the list of reagents for vaccine standardisation. For manufacturers, regulators and the researchers who evaluate influenza vaccines, it means the strain set for the season now explicitly applies to a third production platform.
What happened
EMA’s news item, first published on 30 March 2026 after the Committee for Medicinal Products for Human Use (CHMP) endorsed the recommendations at its March plenary, was last updated on 17 November 2026. The accompanying document, reference EMA/CHMP/BWP/62405/2026, is the output of the Biologics Working Party (BWP) vaccines quality operational expert group (BV-OEG) influenza meeting. It is dated 12 November 2026 and states that the group, having considered WHO surveillance information presented by the WHO Collaborating Centre at the Francis Crick Institute, concluded that the WHO recommendation on vaccine composition for 2026/2027 should be followed.
The document records three amendments after the original March text. Two came in May 2026: one added recommendations for a suitable B/Victoria lineage virus for egg-derived vaccines and for suitable H1N1 and H3N2 viruses for live attenuated vaccines, and a second added a suitable A/H3N2 virus for cell-derived vaccines and a suitable B-lineage virus for live attenuated vaccines. The latest amendment adds recommendations for mRNA influenza vaccines. Each amendment also updated Annex I.
Key details: the recommended strains
The strains are exactly as listed in the EMA document, and they match the WHO recommendation published on 27 February 2026.
| Vaccine platform | A(H1N1)pdm09 | A(H3N2) | B/Victoria lineage |
|---|---|---|---|
| Egg-based or live attenuated | A/Missouri/11/2025-like | A/Darwin/1454/2025-like | B/Tokyo/EIS13-175/2025-like |
| Cell-derived or nucleic acid-based (including mRNA) | A/Missouri/11/2025-like | A/Darwin/1415/2025-like | B/Pennsylvania/14/2025-like |
For manufacture, the group accepted specific candidate viruses. For egg-derived vaccines these include reassortants IVR-278 (derived from A/Switzerland/6849/2025) and IVR-279 (derived from A/Missouri/11/2025) for the H1N1 component, SAN-049A and IVR-285 (both derived from A/Michigan/105/2025) for H3N2, and wild-type B/Perth/115/2025 or B/Tokyo/EIS13-175/2025 for B/Victoria. For cell-derived vaccines the document lists CVR-351 (from A/Tasmania/318/2025) for H1N1, CVR-400 (from A/Darwin/1415/2025) and CVR-388 (from A/Tasmania/787/2025) for H3N2, and wild-type B/Arizona/21/2025 for B/Victoria.
There is no EU recommendation for a B/Yamagata strain. The document says WHO has concluded that including a B/Yamagata antigen is no longer warranted. Where quadrivalent vaccines are still required, for example where the transition to trivalent vaccines is not finished, manufacturers may consider a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus in egg-based or cell-derived inactivated vaccines, following earlier WHO recommendations.
Background and context
WHO announced its northern hemisphere recommendation on 27 February 2026 after a four-day consultation of experts from WHO Collaborating Centres and Essential Regulatory Laboratories within the Global Influenza Surveillance and Response System. WHO groups cell culture-, recombinant protein- and nucleic acid-based vaccines under one strain set, which is why EMA’s mRNA addition uses the same cell-derived strains rather than a separate selection. Scientific American reported on 2 March 2026 that the WHO advice is similar to the previous year’s, that WHO also asked for candidate vaccine viruses to be prepared for H9N2 avian influenza as a pandemic precaution, and that the H3N2 variant known as subclade K appears able to partly evade protection from the current vaccine.
Reaction
Scientific American quoted experts saying that the current shot may still offer some defences against subclade K, and that an mRNA influenza vaccine could be manufactured faster than traditional shots, which would help if new variants emerge late in a season. That is the practical background to EMA now naming mRNA vaccines in the annual composition document.
What it means for researchers, universities and research offices
Manufacturers and regulatory affairs teams. EMA recommends that marketing authorisation holders submit applications to change the composition of centrally authorised seasonal influenza vaccines by 15 June 2026; that date has passed for the strains above. The mRNA amendment of 12 November 2026 carries no separate submission date in the document, so sponsors of mRNA influenza vaccines should check the current procedural guidance for their product. Quality teams working to GMP need the updated Annex I reagent list, which names MHRA (NIBSC), TGA Australia and CBER/FDA as reagent sources, for potency testing and release.
Vaccine-effectiveness and surveillance researchers. The strain set defines the vaccine antigens against which effectiveness studies, serology panels and antigenic characterisation are interpreted. The split between egg-derived A/Darwin/1454/2025 and cell-derived A/Darwin/1415/2025 H3N2 viruses, and between the two B/Victoria viruses, means analyses should record which platform a study population received. With mRNA products now covered, platform-specific effectiveness comparisons become easier to frame against a named strain set.
Clinical trial sponsors and research labs. Sponsors running influenza vaccine trials need the investigational antigen to match the season’s recommended strains, and protocol amendments and reagent orders should be checked against Annex I. Reference laboratories and university virology groups can use the listed candidate vaccine viruses and reagents for assay standardisation. Trial conduct itself sits under ICH E6(R3), while strain and reagent quality sit with the manufacturing side. For a view of how the regulators differ, see the EMA versus FDA comparison, and for the manufacturing-versus-trial quality frameworks, GCP versus GMP.
What happens next
The EMA recommendation applies to the 2026/2027 season. Annex I and the strain tables can be amended again, as the three amendments so far show, so teams should consult the live EMA page for the current version before filing or ordering reagents.
Sources
- European Medicines Agency: EU recommendations for 2026/2027 seasonal flu vaccine composition, updated 17 November 2026
- European Medicines Agency: BV-OEG influenza meeting, EMA/CHMP/BWP/62405/2026, 12 November 2026
- World Health Organization: Recommendations for influenza vaccine composition for the 2026-2027 northern hemisphere season, 27 February 2026
- Scientific American: Here are the flu strains health officials predict could hit hard next season, 2 March 2026







